EyePoint, Inc. EYPT
0.31 USD -0.01 (-4.23%)
Regular-session close
0.31 +0.01 +1.99%
After hours · Nov 13, 7:23 PM ET
0.306 Day range 0.329
0.306 52-week range 18.85
- YTD
- -98.33%
- 1 year
- -97.34%
News
benzinga.com Stifel Maintains Buy on EyePoint, Lowers Price Target to $5 Stifel analyst Annabel Samimy maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $6 to $5.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million. InspireMD (NASDAQ:NSPR) shares…
seekingalpha.com EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript EyePoint, Inc. (EYPT) Q3 2026 Earnings Call Transcript
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to…
zacks.com EyePoint (EYPT) Reports Q3 Loss, Beats Revenue Estimates EyePoint (EYPT) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.85 per share a year ago.
benzinga.com EyePoint Pharmaceuticals Q3 2026 Earnings Call Transcript EyePoint Pharmaceuticals (NASDAQ:EYPT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com EyePoint Pharmaceuticals Q3 EPS $(1.07) Misses $(0.91) Estimate, Sales $756.000K Beat $223.077K Estimate EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.91) by 17.58 percent. This is a 25.88 percent decrease over…
globenewswire.com EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments – Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the positive Phase 2 VERONA trial and…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to…
globenewswire.com EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to…
globenewswire.com EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026 WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT). Such investors are advised to…
zacks.com EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy? EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to…
globenewswire.com EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUCIA topline readout. Levi & Korsinsky is investigating potential securities law…
globenewswire.com Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT) DURAVYU's Phase 3 LUCIA trial missed its primary endpoint and EYPT shares lost nearly 80% of their value in a single session. Levi & Korsinsky is investigating on behalf of shareholders who may have…
defenseworld.net EyePoint (NASDAQ: EYPT) cuts 53% of staff after DURAVYU wet AMD miss What happened EyePoint, Inc. (NASDAQ: EYPT) said on October 19, 2026 that it is shifting its focus to DURAVYU for diabetic macular edema after LUCIA missed its primary endpoint. The board approved a…
gurufocus.com EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint PharmaceuticalsPR NewswireNEW YORK, Oct. 20, 2026
prnewswire.com EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO's favorable result depended on excluding nine DURAVYU…
benzinga.com RBC Capital Maintains Sector Perform on EyePoint, Lowers Price Target to $1 RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Sector Perform and lowers the price target from $5 to $1.
benzinga.com Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.
prnewswire.com EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT) EyePoint Pharmaceuticals shares lost nearly 80% of their value following the disappointing Phase 3 LUCIA trial results for DURAVYU in wet age-related macular degeneration. Levi & Korsinsky is…
benzinga.com Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 300 points on Monday.The Dow traded up 0.06% to 52,031.59 while the NASDAQ jumped 1.24% to 26,465.39.…
benzinga.com EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus EyePoint Inc. (NASDAQ:EYPT) is slashing its workforce by 53% and halting wet age-related macular degeneration clinical trials early following disappointing Phase 3 results.
benzinga.com EyePoint Slashing Workforce, Halting Clinical Trials to Pivot Focus EyePoint cuts 53% of staff and halts wet AMD trials after DURAVYU misses its Phase 3 primary endpoint, pivoting its focus entirely to DME.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…
seekingalpha.com EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript EyePoint, Inc. (EYPT) Discusses LUCIA Phase III Topline Results for DURAVYU in Wet Age-Related Macular Degeneration Prepared Remarks Transcript
benzinga.com Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views U.S. stocks mixed: Nasdaq +1.09%, S&P 500 +0.54%, Dow -0.12%. Tech led gains; utilities lagged. Oil fell, gold rose; Europe lower.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved…
benzinga.com Eyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint – LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement –– Key secondary…
benzinga.com Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsychiatric adverse events; other stocks also fall
benzinga.com This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.
benzinga.com TD Cowen Downgrades EyePoint to Hold, Lowers Price Target to $4 TD Cowen analyst Tara Bancroft downgrades EyePoint (NASDAQ:EYPT) from Buy to Hold and lowers the price target from $20 to $4.
benzinga.com Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
benzinga.com These Analysts Slash Their Forecasts On EyePoint EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoint was not met, secondary endpoints showed progress. Analysts adjust price targets.- benzinga.com Citigroup Maintains Buy on EyePoint, Lowers Price Target to $17 Citigroup analyst Yigal Nochomovitz maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $35 to $17.
benzinga.com RBC Capital Downgrades EyePoint to Sector Perform, Lowers Price Target to $5 RBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perform and lowers the price target from $37 to $5.
benzinga.com Chardan Capital Downgrades EyePoint to Neutral, Lowers Price Target to $5 Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral and lowers the price target from $65 to $5.
benzinga.com Nike, Meta Platforms, INVO Fertility, EyePoint Pharmaceuticals, and Micron: Why These 5 Stocks Are on Investors' Radars Today Major U.S. indices ended lower on Monday, with the Dow Jones Industrial Average falling 0.51% to 53,459.78
benzinga.com Why Is Ocular Therapeutix Stock Gaining Monday? Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release,…
- benzinga.com Jefferies Maintains Buy on EyePoint, Lowers Price Target to $8 Jefferies analyst Kambiz Yazdi maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price target from $30 to $8.
benzinga.com Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consumer staples down 1%. NY Fed's Empire State Index at 20.6.
benzinga.com EyePoint Stock Plummets on Mixed Primary Data From Blindness Drug Study EyePoint reported Phase 3 LUGANO trial results for DURAVYU, highlighting reduced treatment burden despite primary endpoint challenges.
benzinga.com Dow Falls 150 Points; NY Empire State Manufacturing Index Rises In August US stocks mixed, Dow falls 150 points. Dow down 0.31%, NASDAQ up 0.03%, S&P 500 down 0.12%. Tech shares up 0.4%, consumer staples down 0.8%.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved…- benzinga.com EyePoint Reports DURAVYU Non‑Inferior To Aflibercept In Ad Hoc Analysis; Primary BCVA Endpoint Not Met In Full Dataset EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced topline…
- benzinga.com EyePoint Announces Topline Results From LUGANO, First Pivotal Phase 3 Clinical Trial For DURAVYU For Treatment Of Wet Age-Related Macular Degeneration – DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15…